Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
algenpantucel-P
- Development stage
- Phase 2
- Lead developer
- Lumos Pharma
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
HyperAcute-Prostate (algenpantucel-P) is an investigational cancer vaccine developed for the treatment of prostate cancer. It consists of two allogeneic prostate cancer cell lines genetically modified to express alpha-Gal epitopes. The modification is designed to stimulate a robust immune response by leveraging the natural anti-alpha-Gal antibodies present in humans, thereby enhancing recognition and destruction of prostate tumor cells by the immune system. Each cell line provides broad coverage of prostate cancer antigens; they are cultured, harvested, irradiated to prevent replication, and administered separately as a vaccine. Clinical studies have shown that this immunotherapy can induce antibody responses against tumor-associated antigens and may stabilize PSA levels in some patients with advanced disease. The therapy has demonstrated a favorable safety profile in early-phase clinical trials[2].
- Other names
- HyperAcute-Prostate Cancer ImmunotherapyHyperAcute Prostate
02
Targets
Anti-Gal (Alpha-gal epitope-specific antibody)
Beyond the preview
Go deeper on algenpantucel-P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on algenpantucel-P.